Form 4: Fulcrum Therapeutics Director Granted Significant Stock Options

Fulcrum Therapeutics, Inc. Director Kate Haviland was granted 36,000 stock options with an exercise price of $7.38, vesting on the first anniversary of the grant date or earlier.

Summary

• Kate Haviland, a Director of Fulcrum Therapeutics, Inc. (FULC), was granted 36,000 stock options.
• The transaction date for this grant was June 26, 2025.
• The exercise price for these stock options is $7.38 per share.
• The options are scheduled to vest with respect to all shares on the first anniversary of the grant date (June 26, 2026) or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• The expiration date for these stock options is June 25, 2035.
• Following this transaction, Kate Haviland beneficially owns 36,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is a standard practice for aligning management incentives with shareholder interests. It does not contain information that would significantly alter the company's financial outlook or operational status, thus indicating a neutral to slightly positive sentiment due to incentive alignment.

Positives

• The grant of 36,000 stock options to a director aligns management incentives with long-term shareholder interests.
• The options have a 10-year expiration period, providing a long-term incentive for the director to contribute to the company's success.

Negatives

• No direct negatives are indicated in this Form 4 filing, which primarily reports a routine grant of equity.

Risks

• The value of the stock options is entirely dependent on the future performance of Fulcrum Therapeutics, Inc.'s common stock, and they may become worthless if the stock price does not exceed the exercise price.
• Vesting of the options is subject to continued service, meaning the options could be forfeited if the director's service terminates before the vesting conditions are met.

Future Outlook

The stock options are scheduled to vest on the first anniversary of the grant date (June 26, 2026) or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Management Comments

• No specific management comments or statements are included in this Form 4 filing, which is a transactional report of an equity grant.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as other sectors, to align the interests of leadership with long-term shareholder value and to serve as a form of compensation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector.
• The specific terms, such as the exercise price and vesting schedule, are typically determined by the company's compensation committee and are often benchmarked against peer companies to ensure competitive compensation and retention.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are disclosed in this Form 4 filing.

Related Party Transactions

• The grant of stock options to Kate Haviland, a director of Fulcrum Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with long-term shareholder value creation. While it represents potential future dilution if exercised, this is a standard component of executive and director compensation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The granted stock options are scheduled to vest on June 26, 2026, or earlier, subject to the director's continued service.

Key Dates

Keywords

Fulcrum Therapeutics, FULC, stock option, equity grant, insider transaction, Form 4, director compensation, Kate Haviland